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Abstract
Background: Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified
cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for
treating AML. However, HDAC family members that are involved in chemotherapy sensitivities remain unknown. In this
study, we sought to identify members of the HDAC family that are involved in cytarabine sensitivities, and to select the
optimal HDACI that is most efficacious when combined with cytarabine for treating children with AML.
Methodology: Expression profiles of classes I, II, and IV HDACs in 4 pediatric AML cell lines were determined by Western
blotting. Inhibition of class I HDACs by different HDACIs was measured post immnunoprecipitation. Individual down-
regulation of HDACs in pediatric AML cells was performed with lentiviral shRNA. The effects of cytarabine and HDACIs on
apoptosis were determined by flow cytometry analysis.
Results: Treatments with structurally diverse HDACIs and HDAC shRNA knockdown experiments revealed that down-
regulation of both HDACs 1 and 6 is critical in enhancing cytarabine-induced apoptosis in pediatric AML, at least partly
mediated by Bim. However, down-regulation of HDAC2 may negatively impact cytarabine sensitivities in the disease. At
clinically achievable concentrations, HDACIs that simultaneously inhibited both HDACs 1 and 6 showed the best anti-
leukemic activities and significantly enhanced cytarabine-induced apoptosis.
Conclusion: Our results further confirm that HDACs are bona fide therapeutic targets for treating pediatric AML and suggest
that pan-HDACIs may be more beneficial than isoform-specific drugs.
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Introduction
Acute myeloid leukemia (AML) accounts for one-fourth of acute
leukemia in children, but is responsible for more than half of the
leukemia deaths in this patient population [1]. Resistance to
cytarabine (ara-C)-based chemotherapy is a major cause of
treatment failure in this disease [2,3]. Therefore, new therapies
for children with AML are urgently needed. Among the newer
antileukemic agents that have been recently investigated in high-
risk adult AML, histone deacetylase (HDAC) inhibitors [HDACIs,
e.g., valproic acid (VPA) and Vorinostat (SAHA)] are particularly
notable [4,5]. The ability of HDACIs to induce cell differentiation,
cell cycle arrest, and apoptosis in human leukemic cells, but not in
normal cells [6], has stimulated significant interest in their
potential as anti-leukemia agents. Numerous HDACIs have been
developed during the last decade and the majority of these are
being studied in solid tumor and hematological malignancy
clinical trials, including the novel class I-selective HDACIs, MS-
275 and MGCD0103, and pan-HDACIs, LBH-589 and PXD101
[4,5].
Despite the well-characterized molecular and cellular effects of
HDACIs, single-agent activity of this class of drugs has been
modest. Therefore, there is an urgent need for developing
rationally designed drug combinations including HDACIs. In
our previous study [7], we hypothesized that VPA synergizes with
cytarabine, resulting in enhanced antileukemic activities in AML
cells, by inducing apoptosis. We previously examined the impact of
VPA on cytarabine cytotoxicities in 4 pediatric AML cell lines and
9 diagnostic blast samples from children with de novo AML and
demonstrated highly synergistic antileukemic activities of com-
bined cytarabine/VPA in all of the cell lines and diagnostic blast
samples, especially those with t(8;21). Our mechanistic studies
revealed that cooperative induction of DNA damage by the two
agents and induction of Bim by VPA underlay the observed
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17138synergistic antileukemic activities of this drug combination.
Indeed, our results strongly suggested that HDACs are promising
therapeutic targets for pediatric AML, however, which of the
HDAC family members are involved in the synergy between
cytarabine and VPA is not clear.
HDACs comprise a large group of proteins divided into four
classes based on their homologies to yeast HDACs, their
subcellular localizations and their enzymatic activities [8,9]. Class
I HDACs comprise HDACs 1, 2, 3 and 8 and are all homologues
of the yeast rpd3 protein. They are ubiquitously expressed and are
located primarily in the nucleus [8,9]. Class II enzymes comprise
HDACs 4, 5, 6, 7, 9 and 10, which are homologues of the yeast
hda1 protein. These enzymes generally exhibit tissue-specific
expression and shuttle between the cytoplasm and nucleus in
response to cellular signals [10]. Since HDACs 6 and 10 contain
two catalytic sites, these enzymes are sometimes designated as a
separate subclass (Class IIb) [11]. Class III HDACs are comprised
of the seven sirtuins (SIRT1-7), homologues of the yeast SIR2
protein [12]. HDAC11 contains conserved residues that are
shared by both class I and class II enzymes and is classified as a
class IV enzyme [13,14].
HDACs control gene expression through chromatin modifica-
tion. Recent studies have shown that exposure to HDACIs
‘‘resensitizes’’ AML cells to signals for differentiation and/or
apoptosis, making HDACIs particularly promising agents for
AML therapy [4,5,15]. Knockout and siRNA knockdown exper-
iments have suggested that class I HDACs are essential for cancer
cell proliferation and survival, in contrast to class II HDACs 4 and 7
[16,17]. However, inhibition of the class II HDAC6 leads to
acetylation and disruption of the chaperone function of heat-shock
90 (Hsp90) in leukemic cells [18]. Thus, although it is increasingly
apparent that the class I HDAC enzymes are clinically relevant for
cancer, this is less established for the class II enzymes.
In this study, we used 4 pediatric AML cell lines to identify
HDAC family members which are involved in cytarabine
sensitivities, and to select the optimal HDACIs that were most
efficacious against pediatric AML when combined with cytara-
bine. We demonstrated that HDACs 1 and 6 are critical for
cytarabine-induced apoptosis and suggest that pan-HDACIs,
which simultaneously inhibit HDACs 1 and 6, may have the
greatest potential for enhancing cytarabine activities in pediatric
AMLs. Our results further support the use of HDACIs in the
treatment of childhood AML.
Materials and Methods
Drugs
PXD101, LBH-589 and MGCD0103 were purchased from
Selleck Chemicals (Houston, TX). SAHA and MS-275 were
purchased from United States Biological (Swampscott, MA), and
from ChemieTek (Indianapolis, IN), respectively. Cytarabine
(cytosine arabinoside, ara-C) and valproic acid (VPA) were
purchased from Sigma Chemical Company (St Louis, MO).
Cell culture
The THP-1, Kasumi-1, and MV4-11 pediatric AML cell lines
were obtained from American Type Culture Collection (ATCC;
Manassas, VA). The CMS pediatric AML cell line was a gift from
Dr A. Fuse (National Institute of Infectious Diseases, Tokyo,
Japan). The parental and the engineered sublines were cultured in
RPMI 1640 with 10-20% heat-inactivated fetal bovine serum
(FBS; Hyclone Labs, Logan, UT) and 2 mM L-glutamine plus
100 U/mL penicillin and 100 mg/mL streptomycin in a 37uC
humidified atmosphere containing 5% CO2/95% air.
Enzymatic Assays of Class I HDACs Following
Immunoprecipitation (IP)
THP-1 cells were treated with various concentrations of
HDACIs for up to 48 h and lysed in Cell Lysis Buffer
[20 mmol/L Tris-HCl (pH 8), 0.15 mol/L NaCl, 10% glycerol,
and 0.5% NP40] on ice for 2 hours. After centrifugation (12,0006
g for 15 minutes), 500 mg supernatant fraction (cell lysate) was
incubated with 2 mg rabbit IgG, anti-HDAC1, anti-HDAC3
(Bethyl Labs, Montgomery, TX), anti-HDAC2 (CycLex, Nagano,
Japan) or 1000 mg supernatant fraction was incubated with 2 mg
anti-HDAC8 (Santa Cruz Biotechnology, California) overnight at
4uC, followed by incubation with 30 mL of Protein A/GH
Dynabeads (Invitrogen Dynal AS, Oslo, Norway) for 3 hours at
4uC. The beads were washed three times with ice cold PBS and
resuspended in HDAC Assay Buffer [40 mL; 20 mmol/L Tris-HCl
(pH 8), 125 mmol/L NaCl, and 1% glycerol] for measuring
HDAC enzymatic activities using the CycLexH HDACs Deace-
tylase Fluorometric Assay kit (CycLex, Nagano, Japan), or heated
at 95uC for 5 min in 30 ml loading buffer for Western blotting.
Western Blot Analysis
Soluble protein extracts prepared by sonication in hypotonic
buffer (10 mM Tris-Cl, pH 7.0), containing 1% SDS and
proteolytic inhibitors, or immunoprecipitated proteins were
subjected to SDS-polyacrylamide gel electrophoresis. Separated
proteins were electrophoretically transferred to polyvinylidene
difluoride (PVDF) membranes (Thermo Fisher Inc., Rockford, IL)
and immunoblotted with anti-HDAC1 (#2062), -HDAC2
(#2540), -HDAC3 (#2632), -HDAC4 (#2072), -HDAC5
(#2082), -HDAC7 (#2882) (Cell Signalling Technology, Beverly,
MA), -HDAC6 (sc-11420, Santa Cruz Biotechnology, Santa Cruz,
CA), -HDAC8 (H6412), -HDAC10 (H3412), -HDAC11 (H4539),
–acetyl (ac)-tubulin (T7451) (Sigma, Saint Louis, Missouri), -
HDAC9 (SH030228P, ABGENT, San Diego, CA), -ac-Histone
H4, -ac-Histone H3, -ac-Histone H4, -Histone H4, or –beta-actin
antibodies (Upstate Biotechnology, Lake Placid, NY), as described
previously [19,20]. Immunoreactive proteins were visualized with
the Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE), as
described by the manufacturer.
MTT Cytotoxicity Assay
In vitro HDACI cytotoxicities of pediatric AML cell lines were
measured by using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphe-
nyltetrazolium-bromide, Sigma) assays, as previously described
[21]. Briefly, pediatric AML cell lines were cultured in 50 mlo f
RPMI 1640/20% dialyzed fetal bovine serum in 96-well plates.
Cells were incubated at 37uC in the presence of varying
concentrations of MS-275 (8 concentrations, range 0–2 mM),
VPA (8 concentrations, range 0–9.6 mM), or SAHA (8 concen-
trations, range 0–4 mM). After 96 h, MTT was added to a final
concentration of 1 mM. After 4.5 hours, formazan crystals were
dissolved by the addition of 50 ml of 10% SDS in 10 mM HCl.
Optical densities were measured with a visible microplate reader
at 590 nm. IC50 values were calculated as drug concentrations
necessary to inhibit 50% proliferation compared to untreated
control cells. The data for the cell lines are presented as mean
values 6 standard errors from at least 3 independent experiments.
shRNA Knockdown of HDACs in THP-1 cells
HDAC1, HDAC2, HDAC3, HDAC4, and HDAC6 shRNA
lentivirus clones were purchased from the RNAi Consortium
(Sigma-Aldrich) and used to infect THP-1 cells. After selection
with puromycin, a pool of infected cells was expanded and tested
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by Western blotting (designated HDAC1-, HDAC2-, HDAC3-,
HDAC4-, or HDAC6-shRNA). A pool of cells from the negative
control transduction was used as the negative control (designated
NTC-shRNA).
Quantification of Gene Expression by Real-time RT-PCR
Total RNA isolation, cDNA preparation and purification were
as previously reported [19,20,22]. Transcripts for Bcl2L11
(encodes Bim) were quantitated using Taqman probes
(Hs00197982_m1, Applied Biosystems Inc, Foster City, CA),
and a LightCycler real-time PCR machine (Roche, Indianapolis,
IN), based on the manufacturer’s instructions. Real-time PCR
results were expressed as mean values from 3 independent
experiments using the same cDNA preparations and were
normalized to GAPDH.
Assessment of Baseline and Drug Induced Apoptosis
THP-1 cells were treated with HDACIs or cytarabine alone or
in combination for up to 48 h. The cells were harvested,
vigorously pipetted and triplicate samples taken to determine
baseline and drug-induced apoptosis using the Apoptosis Annexin-
V fluorescein isothiocyanate (FITC)/propidium iodide (PI) Kit
(Beckman Coulter; Brea, CA), as previously described [19].
Apoptotic events were recorded as a combination of Annexin-
V+/PI- (early apoptotic) and Annexin-V+/PI+ (late apoptotic/
dead) events and results were expressed as percent of Annexin-V+
cells. Synergy was quantified using the cooperativity index
(cooperativity index = sum of apoptosis of single agent
treatment/apoptosis upon combined treatment). Cooperativity
index ,1, =1, or .1 is termed synergistic, additive, or
antagonistic, respectively [23]. Percent changes of live cells relative
to untreated controls were used to reflect inhibition on cell
proliferation by the agents.
Statistical Analysis
Differences in cell apoptosis between cytarabine- and HDACI-
treated (individually or combined) and untreated cells or between
HDAC shRNA knockdown clones and NTC cells were compared
using the paired t-test. Statistical analyses were performed with
GraphPad Prism 4.0.
Results
Expression Profiles of Classes I, II, and IV HDACs and
HDACI Sensitivities in Pediatric AML Cell Lines
In our previous study, we demonstrated that VPA can enhance
cytarabine-induced apoptosis in different subtypes of pediatric
AML cells, including 4 cell lines (THP-1, Kasumi-1, CMS, and
MV4-11) and 9 diagnostic blasts from children with de novo AML.
Interestingly, Kasumi-1 and MV4-11 sublines were substantially
more sensitive to VPA and showed greater responses to combined
cytarabine/VPA, compared to THP-1 and CMS cells [7]. Our
results strongly suggested that HDACs are promising therapeutic
targets for treating pediatric AML with HDACIs, and that
expression levels of certain HDACs could be responsible for the
differential responses of the pediatric AML cells to VPA and
combined VPA/cytarabine. However, the particular HDAC
family members that impact cytarabine sensitivities have not been
identified.
To begin to address this important question, we first determined
the protein levels for class I, II, and IV HDACs in the 4 pediatric
AML cell lines (THP-1, CMS, Kasumi-1, and MV4-11) used in
our previous study [7]. All class I HDACs (1, 2, 3, and 8) and the
majority of class II HDACs (4, 6, 7, 9, and 10) were detected in the
cell lines, though the levels were somewhat variable. In contrast,
HDAC5 was only detected in THP-1 cells and no detectable
HDAC11 was found in any of the cell lines (Figure 1A).
Besides VPA (inhibits classes I and IIa HDACs, Figure 1B and
reference 7), the 4 cell lines also showed differential sensitivities to
MS-275 (a class I selective-HDACI) and SAHA (a pan-HDACI)
[5], as determined by MTT assays (Figure 1C). Interestingly, the
levels of class I HDACs positively correlated with the IC50s for the
HDACIs and inversely correlated with the responses to combined
VPA/cytarabine among the cell lines [7].
HDACs 5 and 11 are not likely to be involved in cytarabine
sensitivities. While the remaining class II HDACs and any of the
class I enzymes could be relevant to cytarabine antileukemic
activities, based on the relationships between HDAC levels and
responses to combined VPA/cytarabine [7], the impact of class I
HDACs was most robust.
Both Class I Selective- and pan-HDACIs Enhance
Cytarabine-induced Apoptosis in Pediatric AML Cells
To narrow down which HDACs are directly involved in
cytarabine sensitivities in pediatric AMLs, we used equal doses
(IC20s, determined by MTT assays) of the above HDACIs (MS-
275, VPA, and SAHA) with diverse substrate specificities to treat
THP-1 cells, characterized by high level expression of both class I
and II HDACs. Interestingly, treatments of THP-1 cells with MS-
275 resulted in the highest levels of acetylation of both histones H3
and H4, compared to VPA and SAHA (Figure 2A). In contrast,
only treatment with SAHA resulted in hyperacetylation of a-
tubulin, the substrate of HDAC6 (Figure 2A), suggesting the IC20
concentration for this drug was sufficient to inhibit class II HDACs
in the cells. All three HDACIs enhanced cytarabine-induced
apoptosis in THP-1 cells, with MS-275, VPA, and SAHA showing
high, medium, and low levels, respectively, of synergistic
enhancement response (cooperativity index ,1.0, Figure 2B).
These results imply that inhibition of class I HDACs can enhance
cytarabine-induced apoptosis in pediatric AML cells. However,
class II HDACs (e.g., HDAC6) are also implicated since SAHA
was also effective. The variable enhancements of cytarabine-
induced apoptosis by the HDACIs may be due to differential
inhibition of individual HDACs or inhibition of different HDAC
classes.
To test this, enzymatic activities of individual class I HDACs
were measured post immunoprecipitation (IP) in THP-1 cells
treated with IC20 concentrations of the HDACIs. HDACI
treatments did not alter the levels of class I HDAC enzymes in
the cells (Figure 2C). Interestingly, the HDACI treatments
resulted in differential inhibition of class I HDAC enzymes.
Thus, MS-275 treatment resulted in significant inhibition of
HDACs 1, 2, and 3, VPA treatment resulted in significant
inhibition of HDACs 1 and 3, while treatment with SAHA only
inhibited HDAC3 (Figure 2D). It is interesting that the levels of
apoptosis induced by the drug combinations in THP-1 cells
(Figure 2B) inversely correlated with HDAC1 activities
(Figure 2D), suggesting that HDAC1 may play a critical role in
cytarabine-induced apoptosis. In contrast, none of the treatments
resulted in significant inhibition of HDAC8 (Figure 2D),
suggesting that HDAC8 is unlikely to be involved in cytarabine
sensitivity. Together, our results suggest that the enhancement of
cytarabine-induced apoptosis by MS-275 and VPA could be
correlated with inhibition of HDACs 1, 2, and 3, while that by
SAHA could be correlated with inhibition of HDAC3 and class II
HDACs, at least HDAC6.
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Cytarabine-Induced Apoptosis in THP-1 Cells
To further define the roles of the remainder of classes I and II
HDACs in cytarabine sensitivities in pediatric AML, lentiviral
shRNA knockdown of HDACs 1, 2, 3 (class I), 4 (representative of
class IIa), and 6 (representative of class IIb) was performed in
THP-1 cells. As shown in Figure 3A, all shRNAs resulted in
markedly reduced (at least 50%) protein levels of the correspond-
ing HDACs. Interestingly, down-regulation of only HDAC1 or
HDAC6 resulted in significantly increased (,2-fold) cytarabine-
induced apoptosis compared to the NTC-shRNA cells. In contrast,
down-regulation of HDACs 3 and 4 had no appreciable impact on
cytarabine-induced apoptosis. Surprisingly, down-regulation of
HDAC2 resulted in a slight (,30%) yet significantly decreased
apoptosis induced by cytarabine (Figure 3B). These results
demonstrate that inhibition of HDACs 1 and 6 can significantly
enhance cytarabine sensitivities in THP-1 cells, while inhibition of
HDAC2 may negatively impact cytarabine sensitivity.
In our previous study, we found that VPA enhances cytarabine-
induced apoptosis in pediatric AML cells accompanied by
induction of the pro-apoptotic effector, Bim [7]. It is conceivable
that Bim may also enable the enhancement of cytarabine-induced
apoptosis of THP-1 cells resulting from down-regulation of
HDACs 1 and 6. To test this possibility, real-time RT-PCR and
Western blotting were performed in the shRNA stable clones.
Interestingly, knock-down of HDACs 1 and 6 in the HDACs 1-
and 6-shRNA clones was accompanied by substantially increased
BimEL protein levels (2.3- and 1.4-fold, respectively) compared to
the NTC-shRNA cells, while BimEL in the HDACs 2-, 3-, and 4-
shRNA stable clones was largely unchanged (Figure 3C). The
increased BimEL in the HDAC 1- and 6-shRNA stable clones was
accompanied by substantially increased Bcl2L11 transcripts
(encode Bim) (1.9- and 1.6-fold, respectively), suggesting that a
transcriptional mechanism may be responsible for the increased
BimEL levels. Surprisingly, down-regulation of HDACs 2, 3, and
4 also resulted in increased levels for Bcl2L11 transcripts
accompanying unchanged BimEL protein (Figure 3D). These
results indicate that the effects of HDACs 2, 3, and 4 on the
expression of Bim must also involve post-transcriptional mecha-
nisms. Together, our results suggest that both HDACs 1 and 6, but
not HDACs 2, 3, and 4, are promising therapeutic targets for
treating pediatric AML.
HDACIs That Simultaneously Inhibit HDACs 1 and 6
Showed Greater Antileukemic Activities than HDACIs
That Don’t in Pediatric AML Cells
Our results in pediatric AML cell lines suggest that simultaneous
inhibition of HDACs 1 and 6 should result in better anti-leukemic
effects than targeting HDAC1 or HDAC6 alone. To test this
concept, THP-1 cells were treated for 3 h with HDACIs [LBH-
Figure 1. Expression profiles of classes I, II, and IV HDACs and sensitivities to HDACIs of pediatric AML cell lines. Panel A: Protein
extracts from log phase THP-1, Kasumi-1, MV4-11, and CMS cells were subjected to Western blots probed by anti-HDAC or -b-actin antibodies. Panels
B&C: THP-1, Kasumi-1, MV4-11, or CMS cells were cultured at 37uC for 96 h in complete medium with dialyzed fetal bovine serum in 96-well plates,
with a range of concentrations of VPA, MS-275 or SAHA. Viable cell numbers were determined using the MTT reagent and a visible microplate reader.
The IC50 values were calculated as the concentrations of drug necessary to inhibit 50% proliferation compared to control cells cultured in the absence
of drugs. The data are presented as mean values 6 standard errors from at least 3 independent experiments.
doi:10.1371/journal.pone.0017138.g001
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IIa HDACs), MS-275, MGCD0103 (class I selective-HDACIs)],
all at Cmax concentrations from Phase I clinical trials (Table S1)
[24,25,26,27,28,29,30,31,32,33,34,35,36,37]. In order to establish
the effects of these HDACIs on cell proliferation, THP-1 cells post
3 h treatments with the HDACIs were washed three times then
resuspended in drug-free complete media and cultured for up to
24 h. The effects of the HDACIs on HDAC1 activity and
acetylation of a-tubulin by HDAC6 were determined immediately
following the 3 h treatments, whereas effects on cell proliferation
and apoptosis were determined at 24 h. Consistent with previous
reports [4,5], treatments with LBH-589, PXD101, and SAHA, but
not with the other HDACIs, resulted in hyperacetylation of a-
tubulin, the substrate of HDAC6 (Figure 4A). IP followed by
enzymatic assays revealed that both LBH-589 and PXD101
treatments resulted in the greatest inhibition of HDAC1 activities
(.80% relative to control), compared to other HDACIs tested
(Figure 4C). This was accompanied by significantly higher extents
of proliferation inhibition (as reflected in percent decrease of live
cells relative to untreated cells) and apoptosis (Figures 4E&4F).
Essentially the same results were obtained in THP-1 cells when the
HDACI treatments were extended to 24 h, though the levels of
apoptosis induced by the drugs were substantially higher
(Figures 4B, 4D, 4E&F). These results support the notion that
simultaneous inhibition of HDACs 1 and 6 effects high levels of
apoptosis in pediatric AML cells.
DNA Damage and Bim Are Critical Determinants of
HDACI-Induced Apoptosis in Pediatric AML Cells
Efforts were undertaken to better understand the molecular
mechanisms which underlie the anti-leukemic effects of the
aforementioned HDACIs. Reports from our own group and others
demonstratedthat HDACIscaninduceDNAdamage[7,38],which
subsequently triggers apoptosis in leukemia cells. In addition, well
documented HDAC targets, suchas p21, c-Myc, and Bim, may also
be relevant [4]. Interestingly, effects of the HDACIs on p21, c-Myc,
and Bim expression, and in inducing DNA damage (as reflected in
cH2AX) were both drug-dependent and time-dependent, as
reflected in results at 3h and 24h (Figure 5). However, only
induction of cH2AX and Bim paralleled the high levels of apoptosis
upon treatment with LBH-589 and PXD101 (Figure 5). These
results further support our previous conclusion that induction of
Figure 2. Effects of equal doses (IC20) of structurally-diverse HDACIs on acetylation of histones H3 and H4 and a-tubulin, and
cytarabine-induced apoptosis in pediatric AML cells. Panel A: THP-1 cells were treated with equal doses (IC20s, determined by MTT assays) of
MS-275, VPA or SAHA for 48 hrs. Acetylation of histones H3 and H4, and a-tubulin were determined by western blots probed by anti-ac-H3, -ac-H4, -
ac-tubulin, or –H4 antibodies. Panel B: THP-1 cells were treated with cytarabine (900 nM, IC20) or equal doses of MS-275, VPA, or SAHA, alone or in
combination for 48 hrs. Early and late apoptosis events were determined by annexin V/PI staining and flow cytometry analysis. **, p,0.005;
*, p,0.05. Panels C&D: THP-1 cells were treated with equal doses (IC20s) of MS-275, VPA or SAHA for 48 hrs and protein extracts were subjected to
immunoprecipitation with antibodies against class I HDACs, as described in the Materials and Methods. One half of the immunoprecipitated proteins
was subjected to Western blots probed by anti-HDAC1, -HDAC2, -HDAC3, or -HDAC8 antibody (panel C), and the other half was used for measuring
class I HDAC activities (panel D). The data are presented as means of three independent experiments normalized to the non-drug treatment controls.
doi:10.1371/journal.pone.0017138.g002
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HDACIs, whereas the roles of p21 and c-Myc remain to be
established. It is also important to note that induction of Bim by
HDACIs was apparently a late molecular event (i.e., compare
results at 3 h and 24 h), consistent with our previous report [7].
Simultaneous Inhibition of HDACs 1 and 6 Is Critical for
Enhancing Cytarabine-Induced Apoptosis in Pediatric
AML Cells
Our results from the shRNA knockdown experiments implied
that simultaneous inhibition of HDACs 1 and 6 would result in
greater enhancement of cytarabine sensitivities than targeting
HDAC1 or 6 individually. To determine the impact of these
HDACIs on cytarabine cytotoxicity and to mimic clinical
treatment with cytarabine combined with these HDACIs, THP-
1 cells were treated for 3 hours with the HDACIs with and
without cytarabine, all at Cmax concentrations (Table S1),
analogous to experiments in Figure 4. The cells were washed
three times then resuspended in complete media and cultured for
up to 24 h. As expected, both LBH-589 and PXD101 significantly
enhanced cytarabine-induced apoptosis and proliferation inhibi-
tion (as reflected in percent decrease of live cells compared to
untreated cells) of THP-1 cells compared to the other HDACIs
(Figures 6A&6B). This was accompanied by cooperative induction
of DNA damage by the drug combinations, as reflected by the
induction of cH2AX. In contrast, the drug combinations did not
result in further changes for c-Myc (Figure 6C). These results
further support the notion that HDACs 1 and 6 are indeed
therapeutic targets in the treatment of pediatric AML and suggest
that pan-HDACIs may exhibit optimal antileukemic activities at
clinically achievable concentrations when combined with cytara-
bine compared to class I selective-HDACIs.
Discussion
Leukemia is the most common form of childhood cancer and
cancer is the leading cause of death from disease of American
Figure 3. Effects of individual HDACs on cytarabine-induced apoptosis in THP-1 cells. Panel A: THP-1 cells were infected by HDAC1,
HDAC2, HDAC3, HDAC4, HDAC6 or negative (NTC) control shRNA lentiviruses. After selection with puromycin, infected THP-1 cells were expanded
and subjected to Western blotting and probing with anti-HDAC1, -HDAC2, -HDAC3, -HDAC4, -HDAC6, or -b-actin antibody. Panel B: shRNA stable
clones were treated with 900 nM cytarabine for 48 h and early and late apoptosis events were measured using annexin V/PI staining and flow
cytometry analysis. The horizontal line indicates the mean of cytarabine-induced apoptosis in the NTC-shRNA clone. Panel C: Whole cell lysates from
shRNA stable clones were extracted and subjected to Western blotting probed by anti-Bim or -b-actin antibody. Panel D: Total RNAs were isolated
from the shRNA stable clones and reverse transcribed to cDNA. Transcripts for Bcl2L11 (encode Bim) were quantitated using a LightCycler real-time
PCR machine. Real-time PCR results are presented as mean values from 3 independent experiments using the same cDNA preparation and
normalized to GAPDH. **, p,0.005; *, p,0.01.
doi:10.1371/journal.pone.0017138.g003
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in pediatric health. This is particularly relevant to AML in which
progress has lagged significantly in comparison to childhood acute
lymphoblastic leukemia. Resistance to cytarabine-based chemother-
apy is a major cause of treatment failure in this disease [2,3].
Therefore, new therapies for children with AML must be developed.
Figure 4. HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at
Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and
24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells
was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis.
The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected
to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the
Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live
cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and
Methods.
doi:10.1371/journal.pone.0017138.g004
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and can induce apoptosis in leukemia cells but not normal cells
[4,5]. In our previous study, we demonstrated that VPA, an anti-
epileptic agent in both children and adults and a potent HDACI,
synergistically enhanced cytarabine sensitivities in both pediatric
AML cell lines and diagnostic blasts, suggesting that HDACs are
promising therapeutic targets for pediatric AML [7]. However,
individual HDAC family members that are involved in synergistic
cytarabine response in the disease have not been identified.
This study was designed to begin to address this important
question and to select the optimal HDACIs which show the
greatest enhancement on cytarabine sensitivities in pediatric AML
cells. Such information is mechanistically important and has
significant clinical implications, as well. To begin to identify which
HDAC isoforms are involved in cytarabine sensitivity, we
examined the expression profiles of class I, II, and IV HDACs
in 4 pediatric AML cell lines. Our results suggested that HDACs 5
and 11 are unlikely involved in cytarabine sensitivities due to the
lack or marginal expression of these enzymes. Using THP-1 cells
which express high levels of both classes I and II HDACs, we then
used equal doses of three different HDACIs (MS-275, VPA, and
SAHA) with different substrate specificities to further narrow
down the HDAC isoforms likely to be involved in augmenting
cytarabine sensitivity. Results from these studies suggested that
HDAC8 is unlikely to be involved in cytarabine-induced apoptosis
in THP-1 cells since none of the HDACI treatments resulted in
significant enzyme inhibition, although they all enhanced
cytarabine-induced apoptosis.
Results from our shRNA knockdown studies unequivocally
demonstrated that inhibition of HDACs 1 and 6 was pivotal for
sensitizing pediatric AML cells to cytarabine. This could, at least
partly, be mediated by Bim, a BH3-only pro-apoptotic protein.
Bim was classified as an ‘‘activator’’ in view of its purported ability
to act directly and to activate Bax and Bak [39]. It has been well
documented that Bim is critical for HDACI-induced apoptosis of
both solid tumor and leukemia cells [40,41]. Our previous study
strongly suggested that Bim is also critical for cytarabine-induced
apoptosis in pediatric AML cells [7]. Surprisingly, down-
regulation of HDAC2 resulted in significantly decreased apoptosis
induced by cytarabine, even though it was previously reported that
down-regulation of HDAC2 is critical for inducing apoptosis in
cancer cells [42]. In contrast, down-regulation of HDACs 3 and 4
had no effects on cytarabine-induced apoptosis in THP-1 cells.
Together, our results strongly implicate both HDACs 1 and 6 as
the most relevant therapeutic targets for treating pediatric AML
with HDACIs and cytarabine. Studies are underway to determine
the detailed molecular mechanisms responsible for the effects of
HDACs 1, 2, and 6 on cytarabine sensitivities in the disease.
It has been a long-standing debate as to whether isoform
specific- or pan-HDACIs result in better anti-cancer activities
[43,44]. The perception is that isoform-specific HDACIs may offer
clear therapeutic advantages over non-specific classical HDACIs.
Specifically, the premise is that the greater specificity will involve
the modulation of a smaller number of disease-focused genes with
a reduced toxicity profile [44]. However, recent microarray studies
suggested that the pleiotropic antiproliferative and apoptotic
effects of the broad-spectrum HDACIs may be more beneficial
than an isoform-specific drug [16,45]. Our results from shRNA
knockdown studies strongly favor the latter opinion, at least in
pediatric AML, since both HDACs 1 and 6 appear to be critical
factors in determining cytarabine sensitivities in the disease. This
was further supported by our in vitro treatments of pediatric AML
cells with both class I selective- and pan-HDACIs. At clinically
achievable concentrations, only the drugs (LBH-589 and PXD101)
which simultaneously inhibited both HDACs 1 and 6 showed the
best antileukemic activities and significantly enhanced cytarabine-
induced apoptosis. Again, our mechanistic studies suggest that
induction of DNA damage and Bim is critical for the activities of
LBH-589 and PXD101 and their combinations with cytarabine.
Altogether, our results not only confirmed that HDACs are
promising therapeutic targets for pediatric AML, but also
identified HDACs 1 and 6 as the most relevant drug targets.
Accordingly, treating pediatric patients with pan-HDACIs may be
more beneficial than HDAC isoform-specific drugs. Our study
provides compelling rationale for the combination of cytarabine
and HDACIs in pediatric AML clinical trials. It also provides a
strong molecular basis for selecting the optimal HDACIs to
combine with cytarabine. Since many biological features of AML
are shared by adults and children, our results should also apply to
the treatment of adult AML patients, as well. It is extremely
important to note that we used Cmax concentrations for the
HDACIs to combine with cytarabine to prove the concept.
However, Cmax or the maximally tolerated doses of these HDACIs
may not be the optimal doses for combination therapy with
cytarabine. Detailed preclinical studies will be needed to establish
the optimal scheduling and dosing for the combinational therapies
Figure 5. Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated
with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western
blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.
doi:10.1371/journal.pone.0017138.g005
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pediatric AML.
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